Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan

Wu-Lung Chuang; Stella Chin-Shaw Tsai; Yi-Chun Yang; Tsai-Ling Hsieh; Heng-Jun Lin; Yu-Han Huang; Fuu-Jen Tsai; Kuang-Hsi Chang

doi:10.1007/s00210-024-03660-0

Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan

Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov 30. doi: 10.1007/s00210-024-03660-0. Online ahead of print.

Authors

Wu-Lung Chuang^{1

2}, Stella Chin-Shaw Tsai^{3

4}, Yi-Chun Yang⁵, Tsai-Ling Hsieh^{3

6}, Heng-Jun Lin^{7

8}, Yu-Han Huang^{7

8}, Fuu-Jen Tsai^{9

10

11

12}, Kuang-Hsi Chang^{13

14

15}

Affiliations

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua City, 500, Taiwan.
² Division of Endocrinology and Metabolism, Department of Internal Medicine, Lukang Christian Hospital, 505, Lukang , Changhua County, Taiwan.
³ Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung City, 435, Taiwan.
⁴ Post Baccalaureate Medicine, National Chung Hsing University, Taichung City, 402, Taiwan.
⁵ Department of Nursing, Tungs' Taichung MetroHarbor Hospital, Taichung City, 435, Taiwan.
⁶ Department of Medical Research, Tungs' Taichung MetroHarbor Hospital, Taichung City, 435, Taiwan.
⁷ Department of Management office for Health Data, China Medical University Hospital, Taichung City, 404, Taiwan.
⁸ College of Medicine, China Medical University, Taichung City, 404, Taiwan.
⁹ School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung City, 404, Taiwan.
¹⁰ Department of Medical Research, China Medical University Hospital, China Medical University, Taichung City, 404, Taiwan.
¹¹ Division of Medical Genetics, China Medical University Children's Hospital, Taichung City, 404, Taiwan.
¹² Department of Biotechnology and Bioinformatics, Asia University, Taichung City, 413, Taiwan.
¹³ Department of Medical Research, Tungs' Taichung MetroHarbor Hospital, Taichung City, 435, Taiwan. [email protected].
¹⁴ Center for General Education, China Medical University, Taichung City, 404, Taiwan. [email protected].
¹⁵ General Education Center, Nursing and Management, Jen-Teh Junior College of Medicine, 356, Houlong Township, Miaoli County, Taiwan. [email protected].

PMID: 39614895
DOI: 10.1007/s00210-024-03660-0

Abstract

The impact of sodium-glucose cotransporter 2 inhibitors (SLGT2i) usage on reducing the risk of dementia remains uncertain. Our research seeks to establish the association between dementia risk and SLGT2 inhibitors among individuals with diabetes. This study relied on data from the Taiwan National Health Insurance Database (NHIRD), which was established in 1995 coinciding with the launch of the National Health Insurance (NHI) program by the Taiwanese government. The NHI program was implemented to enhance the healthcare system and public health in Taiwan. Patients with type 2 diabetes mellitus (T2DM) administered SGLT2i between 2016 and 2019 were included in the SGLT2i cohort. The comparison cohort consisted of patients who did not receive SGLT2i, propensity score matching by sex, age (in 5-y intervals), index date year, insurance fee, urbanization, comorbidities, and medications, with a 1:1 ratio of the exposure group. SGLT2i users had a significantly lower risk of dementia than non-SGLT2i users after adjusting for age, sex, insurance fees, urbanization, comorbidities, and medications (adjusted HR = 0.53, 95%CI: 0.50-0.57). The results revealed that patients treated with SGLT2i have a lower risk of dementia in Taiwan.

Keywords: Dementia; National Health Insurance Database (NHIRD); Propensity score.; Sodium-glucose cotransporter-2 (SGLT2); Type 2 diabetes mellitus.

Abstract

Grants and funding